Humanized SMART anti-Tac antibody that blocks interleukin-2 binding to activated T cells: Licensee Hoffmann-La Roche has treated the final patients in the Phase

By WIR Staff | Jan 9, 1995 | 8:00 AM GMT

Protein Design Labs Inc. (PDLI), Mountain View,

Read the full 75 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

Article Purchase

This article may not be distributed to non-subscribers

More Info >PURCHASE